论文部分内容阅读
目的 :研究二氢可待因控释片对晚期癌痛病人的镇痛作用。方法 :4 7例经病理学确诊的中晚期癌症病人 ,采用随机临床试验 ,口服二氢可待因控释片 ,每次 60～ 1 2 0mg ,每 1 2h一次 ,日剂量 <2 4 0mg ,连用 7d。资料采用t检验或卡方检验作统计处理。结果 :二氢可待因控释片每 1 2h口服一次 ,可以有效地控制晚期癌症慢性中度以上疼痛 ,临床镇痛总有效率为 1 0 0 %。主要不良反应有头晕 ,恶心 ,呕吐 ,胃部不适 ,便秘。结论 :二氢可待因控释片对晚期癌痛有明显的镇痛作用 ,药效持续时间长 ,不良反应小 ,使用方便
Objective: To study the analgesic effect of hydrocodone controlled release tablets on patients with advanced cancer pain. Methods: Forty-seven patients with pathologically diagnosed advanced and advanced stage cancer were randomized to receive a controlled dose of dihydrocodeine 60 to 120 mg once daily for 14 days. The daily dose was less than 240 mg, Used together 7d. Data using t test or chi-square test for statistical processing. Results: The controlled release tablets of dihydrocodeine were given orally once every 12 hours, which could effectively control the pain of patients with advanced cancer with chronic moderate degree and the total effective rate of clinical pain was 100%. The main adverse reactions are dizziness, nausea, vomiting, stomach upset, constipation. Conclusion: The hydrocodone controlled release tablet has obvious analgesic effect on advanced cancer pain, long duration of efficacy, little adverse reaction, easy to use